Table 3 Adverse events of interest by grade

From: Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial

 

m-FOLFOXIRI + cetuximab (n = 175)

m-FOLFOXIRI + bevacizumab (n = 176)

 

Grade 1–2 n (%)

Grade 3–4 n (%)

Grade 1–2 n (%)

Grade 3–4 n (%)

Any event

24 (13.7)

150 (85.7)

22 (12.5)

154 (87.5)

Anaemia

79 (45.1)

11 (6.3)

94 (53.4)

8 (4.5)

Thrombocytopenia

78 (44.6)

4 (2.3)

69 (39.2)

2 (1.1)

Nausea

72 (41.1)

11 (6.3)

78 (44.3)

11 (6.3)

Vomiting

17 (9.7)

1 (0.6)

28 (15.9)

3 (1.7)

Diarrhea

85 (48.6)

21 (12.0)

87 (49.4)

14 (8.0)

Stomatitis

85 (48.6)

17 (9.7)

71 (40.3)

4 (2.3)

Neutropenia

56 (32.0)

98 (56.0)

58 (33.0)

96 (54.5)

Febrile neutropenia

–

15 (8.6)

 

19 (10.8)

Neurotoxicity

119 (68.0)

12 (6.9)

119 (67.6)

8 (4.5)

Fatigue

46 (26.3)

12 (6.9)

53 (30.1)

11 (6.3)

Anorexia

87 (49.7)

21 (12.0)

80 (45.5)

19 (10.8)

Fever

23 (13.1)

0

40 (22.7)

0

Alopecia

64 (36.6)

–

70 (39.8)

–

Hand-foot syndrome

15 (8.6)

5 (2.9)

8 (4.5)

1 (0.6)

Rash acneiform

111 (63.4)

23 (13.1)

5 (2.8)

0

Hypomagnesaemia

92 (52.6)

7 (4.0)

31 (17.6)

0

Hypokalaemia

51 (29.1)

23 (13.1)

35 (19.9)

11 (6.3)

Hypertension

54 (30.9)

31 (17.7)

65 (36.9)

59 (33.5)

  1. m-FOLFOXIRI modified 5-FU, leucovorin, oxaliplatin and irinotecan.
Back to article page